IL17A and Chronic mucocutaneous candidosis: This enhancement would inhibit interleukin (IL)-17-producing T-cell production and may develop chronic mucocutaneous candidiasis (Immunodeficiency 31C, OMIM # 614162) (Liu et al., 2011).